Table 1.
Demographics and baseline characteristics (N = 34)
| Characteristics | Values |
|---|---|
| Sex, n (%) | |
| Male | 18 (52.9) |
| Female | 16 (47.1) |
| Age at diagnosis (years), n (%) | |
| <60 | 9 (26.5) |
| >60 | 25 (73.5) |
| Duration of symptoms, n (%) | |
| <5 weeks | 7 (20.6) |
| 5–24 weeks | 13 (38.2) |
| 25–52 weeks | 5 (14.7) |
| >1 year | 9 (26.5) |
| Antibody status, n (%) | |
| HMGCR | 15 (44.1) |
| SRP | 6 (17.6) |
| Negative | 12 (35.3) |
| Statin use, n (%) | |
| Previous | 5 (14.7) |
| Current | 20 (58.8) |
| Never | 7 (20.6) |
| Initial CK | |
| Median | 6546 U/l |
| Range | 344–211 066 U/l |
| Initial hip flexor strengtha (grade 0–3), n (%) | |
| Grade 3 | 0 (0.0) |
| Grade 2 | 8 (23.5) |
| Grade 1 | 17 (50.0) |
| Grade 0 | 9 (26.5) |
| Initial treatment, n (%) | |
| GC alone | 14 (41.2) |
| GC + IVIG | 9 (26.5) |
| GC + cs-DMARDs | 10 (29.4) |
| Initial IVMP, n (%) | |
| Yes | 16 (47.1) |
| No | 18 (52.9) |
| Initial use of cs-DMARDs, n (%) | |
| Yes | 13 (38.2) |
| No | 21 (61.8) |
| Early IVIG, n (%) | |
| Yes | 10 (29.4) |
| No | 24 (70.6) |
a
Due to the small number of subjects in the study, we limited the number of grades of the hip flexors in our cohort by combining MRC grades 0–2 into one group.